US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CytoDyn Inc.

0.3200

0.0000

Volume:1.14M

Turnover:369.79K

Market Cap:401.17M

PE:-1.55

High:0.3300

Open:0.3200

Low:0.3110

Close:0.3200

52wk High:0.4945

52wk Low:0.1045

Shares:1.25B

Float Shares:1.25B

Volume Ratio:0.65

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2068

EPS(LYR):-0.2868

ROE:1659.17%

ROA:21.88%

PB:-4.03

PE(LYR):-1.12

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

CytoDyn Reaches Settlement in Securities Class Action Lawsuit

CytoDyn Reports Prolonged Survival With Leronlimab in Metastatic Triple-Negative Breast Cancer

BRIEF-CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing

Cytodyn Inc Files for Offering of up to 120 Mln Shares of Common Stock by Selling Stockholder - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CYDY"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYDY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYDY\",,,,,undefined,":{"symbol":"CYDY","market":"US","secType":"STK","nameCN":"CytoDyn Inc.","latestPrice":0.32,"timestamp":1764968400000,"preClose":0.32,"halted":0,"volume":1143930,"delay":15,"floatShares":1252865057,"shares":1253645452,"eps":-0.206843,"marketStatus":"Market Closed","change":0,"latestTime":"12-05 16:00:00 EST Delay","open":0.32,"high":0.33,"low":0.311,"amount":369789.3357000001,"amplitude":0.059375,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.206843,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.32,"volumeRatio":0.652232442094757},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYDY\",,,,,undefined,":{"symbol":"CYDY","floatShares":1252865057,"roa":"21.88%","roe":"1659.17%","lyrEps":-0.286757,"volumeRatio":0.652232442094757,"shares":1253645452,"dividePrice":0,"high":0.33,"amplitude":0.059375,"preClose":0.32,"low":0.311,"week52Low":0.104475,"pbRate":"-4.03","week52High":0.4945,"institutionHeld":0,"latestPrice":0.32,"eps":-0.206843,"divideRate":0,"volume":1143930,"delay":15,"ttmEps":-0.206843,"open":0.32,"prevYearClose":0.1097,"prevWeekClose":0.3282,"prevMonthClose":0.3282,"prevQuarterClose":0.26,"fiveDayClose":0.3282,"twentyDayClose":0.25,"sixtyDayClose":0.2935},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYDY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-14","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736830800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-10-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1728964800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723694400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1713153600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-01-16","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1705381200000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYDY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CYDY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYDY\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588786557","title":"CytoDyn Reaches Settlement in Securities Class Action Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2588786557","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588786557?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595811,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. has reached an agreement in principle to resolve a securities class action lawsuit that was initially filed in March 2021 against the company and certain former officers. The case, pending in the United States District Court for the Western District of Washington and titled Courter et al. v. CytoDyn Inc. et al., is subject to final court approval. The settlement is expected to provide clarity and finality for the company and its stakeholders. CytoDyn stated that resolving the litigation allows the company to focus on advancing its clinical development programs, including new Phase II studies for leronlimab in metastatic colorectal cancer and metastatic triple-negative breast cancer. Additional information has been included in the company's filings with the Securities and Exchange Commission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL65ywfw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","BK4585","IE00BGHQF748.EUR","BK4588","BK4139","BK4112","IE00BKPKM429.USD","CYDY","LU2095319765.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2585566467","title":"CytoDyn Reports Prolonged Survival With Leronlimab in Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2585566467","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585566467?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:30","pubTimestamp":1763991025,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. has announced that it will present new clinical data on leronlimab in patients with metastatic or locally advanced triple-negative breast cancer at the upcoming San Antonio Breast Cancer Symposium, taking place December 9-12, 2025. The presentation, led by Dr. Milana V. Dolezal from Stanford University School of Medicine, will focus on prolonged survival following immune checkpoint inhibitor therapy with or after leronlimab treatment. According to the company, the data suggest that leronlimab may increase PD-L1 levels, potentially improving the efficacy of immune checkpoint inhibitors in this patient population. The poster will be available on December 12, 2025, and materials will be posted to CytoDyn's website following the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL3tZGVM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","LU0314104364.USD","IE00B3QW5Z07.USD","CYDY","LU2210150020.SGD","BK4112","BK4585","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD"],"gpt_icon":0},{"id":"2581179808","title":"BRIEF-CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581179808","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581179808?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:30","pubTimestamp":1762295403,"startTime":"0","endTime":"0","summary":"BRIEF-CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC FilingNov 4  - Cytodyn Inc CYDY.PK:CYTODYN INC FILES FOR OFFERING OF UP TO 120 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - SEC FILINGSource text: [ID:n0001104659-25-106415]Further company coverage: CYDY.PK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYDY"],"gpt_icon":0},{"id":"2581798373","title":"Cytodyn Inc Files for Offering of up to 120 Mln Shares of Common Stock by Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581798373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581798373?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:17","pubTimestamp":1762294624,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYDY","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CYDY\",params:#limit:6,delay:false,,,undefined,":[]}}